MSD’s subcutaneous Keytruda non-inferior to IV version of blockbuster drug
MSD’s subcutaneous (SC) Keytruda (pembrolizumab) has shown non-inferior pharmacokinetics (PK) to the intravenous (IV) version of the company’s blockbuster therapy…
All articles by Joshua Silverwood
Joshua Silverwood
-
-
Emalex eyes FDA approval for Tourette syndrome therapy after Phase III success
Emalex Biosciences is eyeing approval for its Tourette syndrome therapy after it achieved its primary and secondary endpoints in a…
-
“Digital genocide”: BMJ post alleges patient data deletion amid DEI purge
The US government’s drive to eradicate wording relating to Diversity, Equity and Inclusion (DEI) as well as ‘gender ideology’ from…
-
Pfizer’s colon cancer combo approval further supported by Phase III win
Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving progression-free survival (PFS) in…
-
ITM’s radiotherapeutic beats out standard-of-care in Phase III trial
ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)…
-
European supergroup launches to tackle diversity in clinical trials
A new pan-European initiative aimed at creating a new less fragmented and more democratic ecosystem for clinical trials across the…
-
XBiotech halts all rheumatology research after missing Phase II endpoints
XBiotech’s stock price has taken a hit after it announced a complete halt to its clinical program in rheumatological diseases…
-
Novo Nordisk takes a hit as CagriSema underperforms in weight loss
Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of expectations…
-
CTO Europe 2024: keep the burden of trials away from patients, say experts
Major themes of taking the burden of oncological clinical trials away from the patients themselves to stabilise and streamline research…
-
New Amsterdam stock jumps as LDL-C lowering drug scores again at Phase III
New Amsterdam Pharma’s obicetrapib has exceeded company expectations in the Phase III BROADWAY trial in adult patients with atherosclerotic cardiovascular…